Secretome Therapeutics – Weekly Recap

Secretome Therapeutics is the focus of this weekly summary of notable developments, with the company advancing its lead neonatal cardiac progenitor cell therapy candidate, STM-01, for Duchenne-associated cardiomyopathy. Over the past week, Secretome reported new external funding and outlined an expanded investor outreach strategy.

Secretome Therapeutics disclosed that it has been awarded $250,000 in non-dilutive venture funding from Parent Project Muscular Dystrophy through the PPMD Venture Pathways program. The capital is earmarked to support early development of STM-01, signaling targeted backing from a disease-focused advocacy group in the Duchenne muscular dystrophy space.

This support is viewed as a form of external validation for Secretome’s rare disease and cardiomyopathy-focused platform, even though the absolute funding amount is modest. The involvement of PPMD may enhance Secretome’s visibility among stakeholders and potentially improve access to additional grant-based or strategic capital over time.

In parallel, the company announced plans to participate in several investor-centric healthcare conferences in March and April 2026, including Guggenheim Securities’ Healthcare Private Biopharma Company Virtual 1×1 Day and Piper Sandler’s Spring Biopharma Symposium in Boston. Secretome aims to use these events to engage directly with investors and industry leaders about its development strategy and STM-01 progress.

These conference appearances are designed to increase the company’s profile within the biopharma investment community and gather feedback on its rare disease cell therapy approach. They may also help Secretome assess market appetite ahead of potential future financings or strategic transactions related to STM-01 or its broader platform.

Taken together, the week’s developments underscore Secretome Therapeutics’ continued strategic focus on Duchenne-associated cardiomyopathy and its effort to combine advocacy-group partnerships with heightened investor engagement. The new non-dilutive funding and planned conference participation modestly strengthen the company’s position as it advances its early-stage cell therapy program.